DPP4 and atherosclerosis: Inhibition of EAT/PVAT thickness and inflammation is one of the pharmacological mechanisms by which many drugs inhibit the development of atherosclerosis, including DPP4 inhibitors (such as alogliptin, saxagliptin, sitagliptin, and teneligliptin, GLP-1R agonists (such ase dulaglutide, exenatide, liraglutide, and semaglutide), and SGLT-2i (such as canagliflozin, dapagliflozin, empagliflozin, ipragliflozin, and luseogliflozin).